Derivation and characterization of human fetal MSCs: An alternative cell source for large-scale production of cardioprotective microparticles

Journal of Molecular and Cellular Cardiology

Volumn 48, Issue 6, 2010, Pages 1215-1224

  Lai, Ruenn Chai ^a,b   Arslan, Fatih ^c   Tan, Soon Sim ^a   Tan, Betty ^d   Choo, Andre ^e   Lee, May May ^e   Chen, Tian Sheng ^a   Teh, Bao Ju ^a   Eng, John Kun Long ^f   Sidik, Harwin ^a   Tanavde, Vivek ^d   Hwang, Wei Sek ^g   Lee, Chuen Neng ^b   Oakley, Reida Menshawe El ^b   Pasterkamp, Gerard ^c   de Kleijn, Dominique P V ^c,h   Tan, Kok Hian ^g   Lim, Sai Kiang ^a,b  

^a INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d BIOINFORMATICS INSTITUTE   (Singapore)

^e AGENCY FOR SCIENCE   (Singapore)

^f NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^g KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^h ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Cardioprotection; Fetal mesenchymal stem cells; Microparticles; Paracrine secretion

Indexed keywords

CELL PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN TRA1 60; TELOMERASE; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG;

ADIPOCYTE; ARTICLE; CARTILAGE CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; EMBRYO; EMBRYONIC STEM CELL; ENZYME ACTIVITY; FETUS; FETUS CELL; GENE EXPRESSION PROFILING; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CELL; LIVER CELL; MESENCHYMAL STEM CELL; OSTEOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REPERFUSION INJURY;

ANIMALS; ANTIGENS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EMBRYONIC STEM CELLS; GENE EXPRESSION PROFILING; HUMANS; MESENCHYMAL STEM CELLS; MICE; MICROSPHERES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARTICLE SIZE; REPERFUSION INJURY; SWINE; TISSUE DISTRIBUTION;

SUIDAE;

EID: 77952673860     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.12.021     Document Type: Article

References (59)

1. Le Blanc K., Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy 2005, 7:36-45.
2. Minguell J.J., Erices A. Mesenchymal stem cells and the treatment of cardiac disease. Exp. Biol. Med. (Maywood) 2006, 231:39-49.
3. Schuleri K.H., Boyle A.J., Hare J.M. Mesenchymal stem cells for cardiac regenerative therapy. Handb. Exp. Pharmacol. 2007, 195-218.
4. Abdel-Latif A., Bolli R., Tleyjeh I.M., Montori V.M., Perin E.C., Hornung C.A., et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch. Intern. Med. 2007, 167:989-997.
5. Mazhari R., Hare J.M. Advances in cell-based therapy for structural heart disease. Prog. Cardiovasc. Dis. 2007, 49:387-395.
6. Ohnishi S., Nagaya N. Prepare cells to repair the heart: mesenchymal stem cells for the treatment of heart failure. Am. J. Nephrol. 2007, 27:301-307.
7. Behfar A., Terzic A. Optimizing adult mesenchymal stem cells for heart repair. J. Mol. Cell Cardiol. 2007, 42:283-284.
8. Atsma D.E., Fibbe W.E., Rabelink T.J. Opportunities and challenges for mesenchymal stem cell-mediated heart repair. Curr. Opin. Lipidol. 2007, 18:645-649.
9. Gnecchi M., He H., Liang O.D., Melo L.G., Morello F., Mu H., et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat. Med. 2005, 11:367-368.
10. Caplan A.I., Dennis J.E. Mesenchymal stem cells as trophic mediators. J. Cell Biochem. 2006, 98:1076-1084.
11. Kinnaird T., Stabile E., Burnett M.S., Shou M., Lee C.W., Barr S., et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004, 109:1543-1549.
12. Leedham S.J., Brittan M., McDonald S.A., Wright N.A. Intestinal stem cells. J Cell Mol Med 2005, 9:11-24.
13. Togel F., Hu Z., Weiss K., Isaac J., Lange C., Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am. J. Physiol. Renal Physiol. 2005, 289:F31-F42.
14. Patschan D., Plotkin M., Goligorsky M.S. Therapeutic use of stem and endothelial progenitor cells in acute renal injury: ca ira. Curr. Opin. Pharmacol. 2006, 6:176-183.
15. Miyahara Y., Nagaya N., Kataoka M., Yanagawa B., Tanaka K., Hao H., et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat. Med. 2006, 12:459-465.
16. Gnecchi M., He H., Noiseux N., Liang O.D., Zhang L., Morello F., et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006, 20:661-669.
17. Mayer H., Bertram H., Lindenmaier W., Korff T., Weber H., Weich H. Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation. J. Cell Biochem. 2005, 95:827-839.
18. Nakagami H., Maeda K., Morishita R., Iguchi S., Nishikawa T., Takami Y., et al. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2542-2547.
19. Van Overstraeten-Schlogel N., Beguin Y., Gothot A. Role of stromal-derived factor-1 in the hematopoietic-supporting activity of human mesenchymal stem cells. Eur. J. Haematol. 2006, 76:488-493.
20. Cheng L., Qasba P., Vanguri P., Thiede M.A. Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells. J. Cell Physiol. 2000, 184:58-69.
21. Lian Q., Lye E., Suan Yeo K., Khia Way Tan E., Salto-Tellez M., Liu T.M., et al. Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs. Stem Cells 2007, 25:425-436.
22. Sze S.K., de Kleijn D.P., Lai R.C., Khia Way Tan E., Zhao H., Yeo K.S., et al. Elucidating the secretion proteome of human embryonic stem cell-derived mesenchymal stem cells. Mol. Cell Proteomics 2007, 6:1680-1689.
23. Arslan F., Smeets M.B., O'Neill L.A., Keogh B., McGuirk P., Timmers L., et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010, 121:80-90.
24. Thery C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009, 9:581-593.
25. Ethical, legal and social issues in human stem cell research, reproductive and therapeutic cloning. Singapore Bioethics Advisory Committee Report 2002.
26. Wege H., Chui M.S., Le H.T., Tran J.M., Zern M.A. SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity. Nucleic Acids Res. 2003, 31:E3.
27. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
28. Tsai M.S., Lee J.L., Chang Y.J., Hwang S.M. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum. Reprod. 2004, 19:1450-1456.
29. Guillot P.V., Gotherstrom C., Chan J., Kurata H., Fisk N.M. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells 2007, 25:646-654.
30. Peng H.H., Wang T.H., Chao A.S., Chang S.D. Isolation and differentiation of human mesenchymal stem cells obtained from second trimester amniotic fluid; experiments at Chang Gung Memorial Hospital. Chang Gung Med. J. 2007, 30:402-407.
31. Roubelakis M.G., Pappa K.I., Bitsika V., Zagoura D., Vlahou A., Papadaki H.A., et al. Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev. 2007, 16:931-952.
32. Yen M.L., Chien C.C., Chiu I.M., Huang H.I., Chen Y.C., Hu H.I., et al. Multilineage differentiation and characterization of the human fetal osteoblastic 1.19 cell line: a possible in vitro model of human mesenchymal progenitors. Stem Cells 2007, 25:125-131.
33. Jo C.H., Kim O.S., Park E.Y., Kim B.J., Lee J.H., Kang S.B., et al. Fetal mesenchymal stem cells derived from human umbilical cord sustain primitive characteristics during extensive expansion. Cell Tissue Res. 2008, 334:423-433.
34. Kermani A.J., Fathi F., Mowla S.J. Characterization and genetic manipulation of human umbilical cord vein mesenchymal stem cells: potential application in cell-based gene therapy. Rejuvenation Res. 2008, 11:379-386.
35. Poloni A., Rosini V., Mondini E., Maurizi G., Mancini S., Discepoli G., et al. Characterization and expansion of mesenchymal progenitor cells from first-trimester chorionic villi of human placenta. Cytotherapy 2008, 10:690-697.
36. Wang X.Y., Lan Y., He W.Y., Zhang L., Yao H.Y., Hou C.M., et al. Identification of mesenchymal stem cells in aorta-gonad-mesonephros and yolk sac of human embryos. Blood 2008, 111:2436-2443.
37. Zhang Z.Y., Teoh S.H., Chong M.S., Schantz J.T., Fisk N.M., Choolani M.A., et al. Superior osteogenic capacity for bone tissue engineering of fetal compared to perinatal and adult mesenchymal stem cells. Stem Cells 2009, 27:126-137.
38. Tang Y.L., Zhao Q., Qin X., Shen L., Cheng L., Ge J., et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann. Thorac. Surg. 2005, 80:229-236. discussion 36-7.
39. Javazon E.H., Beggs K.J., Flake A.W. Mesenchymal stem cells: paradoxes of passaging. Exp. Hematol. 2004, 32:414-425.
40. Barry F.P., Murphy J.M. Mesenchymal stem cells: clinical applications and biological characterization. Int. J. Biochem. Cell Biol. 2004, 36:568-584.
41. Majumdar M.K., Keane-Moore M., Buyaner D., Hardy W.B., Moorman M.A., McIntosh K.R., et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J. Biomed. Sci. 2003, 10:228-241.
42. Meziani F., Tesse A., Andriantsitohaina R. Microparticles are vectors of paradoxical information in vascular cells including the endothelium: role in health and diseases. Pharmacol. Rep. 2008, 60:75-84.
43. Redman C.W., Sargent I.L. Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta 2008, 29(Suppl. A):S73-S77.
44. Zwicker J.I. Tissue factor-bearing microparticles and cancer. Semin. Thromb. Hemost. 2008, 34:195-198.
45. Aharon A., Brenner B. Microparticles, thrombosis and cancer. Best Pract. Res. Clin. Haematol. 2009, 22:61-69.
46. Burnier L., Fontana P., Kwak B.R., Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb. Haemost. 2009, 101:439-451.
47. Castellana D., Kunzelmann C., Freyssinet J.M. Pathophysiologic significance of procoagulant microvesicles in cancer disease and progression. Hamostaseologie 2009, 29:51-57.
48. Chironi G.N., Boulanger C.M., Simon A., Dignat-George F., Freyssinet J.M., Tedgui A. Endothelial microparticles in diseases. Cell Tissue Res. 2009, 335:143-151.
49. Horstman L.L., Jy W., Bidot C.J., Nordberg M.L., Minagar A., Alexander J.S., et al. Potential roles of cell-derived microparticles in ischemic brain disease. Neurol. Res. 2009, 31:799-806.
50. Esmon C.T. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev. 2009, 23:225-229.
51. Davizon P., Lopez J.A. Microparticles and thrombotic disease. Curr. Opin. Hematol. 2009, 16:334-341.
52. Al-Nedawi K., Meehan B., Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle 2009, 8:2014-2018.
53. Doeuvre L., Plawinski L., Toti F., Angles-Cano E. Cell-derived microparticles: a new challenge in neuroscience. J. Neurochem. 2009, 110:457-468.
54. Sabatier F., Camoin-Jau L., Anfosso F., Sampol J., Dignat-George F. Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence. J. Cell Mol. Med. 2009, 13:454-471.
55. Stein E., McMahon B., Kwaan H., Altman J.K., Frankfurt O., Tallman M.S. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract. Res. Clin. Haematol. 2009, 22:153-163.
56. Milsom C., Rak J. Tissue factor and cancer. Pathophysiol. Haemost. Thromb. 2008, 36:160-176.
57. Hartvigsen K., Chou M.Y., Hansen L.F., Shaw P.X., Tsimikas S., Binder C.J., et al. The role of innate immunity in atherogenesis. J. Lipid Res. 2009, 50 Suppl:S388-S393.
58. Benameur T., Andriantsitohaina R., Martinez M.C. Therapeutic potential of plasma membrane-derived microparticles. Pharmacol. Rep. 2009, 61:49-57.
59. Knight D.R. Editorial overview: cardioprotective drugs for myocardial ischemic injury-a therapeutic area at risk. Curr. Opin. Investig. Drugs 2007, 8:190-192.